Between 1977 and 2005, 28 cases of potential links between maternal dydrogesterone use during pregnancy and congenital birth defects were reported. The types of defects were very diverse, with no evidence of a pattern of abnormalities. The data do not provide evidence for congenital malformations associated with dydrogesterone use.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.earlhumdev.2008.12.016 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Birth defects reporting and the use of dydrogesterone: a disproportionality analysis from the World Health Organization pharmacovigilance database (VigiBase).
Hum Reprod Open
January 2025
Regional Center of Pharmacovigilance, Pharmacology Department, Cochin Hospital, AP-HP.Centre-Université Paris Cité, Paris, France.
Study Question: Is there an association between dydrogesterone exposure during early pregnancy and the reporting of birth defects?
Summary Answer: This observational analysis based on global safety data showed an increased reporting of birth defects, mainly hypospadias and congenital heart defects (CHD), in pregnancies exposed to dydrogesterone, especially when comparing to progesterone.
What Is Known Already: Intravaginal administration of progesterone is the standard of care to overcome luteal phase progesterone deficiency induced by ovarian stimulation in ART. In recent years, randomized controlled clinical trials demonstrated that oral dydrogesterone was non-inferior for pregnancy rate at 12 weeks of gestation and could be an alternative to micronized vaginal progesterone.
EFFECTIVENESS OF COMBINED SURGICAL AND HORMONAL THERAPY IN TREATMENT OF ENDOMETRIOMAS.
Georgian Med News
October 2024
3Faculty of Medicine at University Geomedi, Tbilisi, Georgia.
Introduction: Endometrial cyst, or endometrioma, is a specific form of endometriosis that often reveals with severe symptoms and requires ongoing treatment. High rate of recurrence after surgical intervention presents a significant challenge in the management of this disease.
Aim Of The Study: Aim of the study was to determine the effectiveness of combined therapy (surgical and hormonal) of endometrioma in terms of development of recurrences, the rate of pregnancy and change in pain intensity.
Oral dydrogesterone along with vaginal micronized progesterone supplementation for luteal phase support in IVF patients, and its impact on pregnancy and live birth rates: a prospective randomized trial.
BMC Pregnancy Childbirth
December 2024
One Day Medical Center, Via Attilio Ambrosini 114, Rome, 00147, Italy.
Background: A normal luteal function is an essential factor for maintaining pregnancy; luteal phase deficiency decreases embryo implantation and pregnancy rate and increases the early miscarriage rate. In stimulated in vitro fertilization-embryo transfer (IVF-ET) patients, luteal phase support (LPS) is achieved by the exogenous supplementation with progesterone to increase endometrial receptivity and pregnancy. While several protocols exist, no commonly accepted protocol has been established for optimal luteal support after IVF-ET to date, the purpose of this study was to investigate the effect of two different luteal phase support protocols in patients undergoing assisted reproductive technologies.
View Article and Find Full Text PDFEfficacy and safety of different progestogens in women with first threatened miscarriage: A network meta-analysis.
Int J Gynaecol Obstet
December 2024
Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Threatened miscarriage is defined as early vaginal bleeding before 12 weeks of gestational age and can occur in any pregnancy regardless of maternal age, race, comorbidities, lifestyle, or socioeconomic status, and about one-quarter of threatened miscarriages proceed to complete miscarriage. To assess the relative effectiveness and safety of different progestogens in women with first threatened miscarriage, using a network meta-analysis. A systematic search was conducted in PubMed, EMBASE, and Cochrane Library databases from inception to April 2023.
View Article and Find Full Text PDFIs oral dydrogesterone equivalent to vaginal micronized progesterone for luteal phase support in women receiving oocyte donation?
Reprod Biol Endocrinol
December 2024
Department of Reproductive Medicine, University of Lille, CHU Lille, Lille, 59000, France.
Research Question: To determine whether the use of oral dydrogesterone (DYD) in luteal phase support (LPS) during an artificial cycle provides equivalent clinical and ongoing pregnancy, delivery and miscarriage rates as micronized vaginal progesterone (MVP) in oocyte donation recipients.
Design: This was a retrospective observational study of prospectively collected data from the assisted reproductive technology (ART) Department of Lille University Hospital from July 2018 to July 2022. All recipients underwent endometrial preparation by an artificial cycle.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!